Basal Cell Carcinoma Superficial

• FDA approval · 2024-09-16
  FDA Approved: ZYCLARA — Supplemental Application (Bausch Health US, LLC)

  FDA approved a supplemental application for ZYCLARA (imiquimod) filed by Bausch Health US, LLC.

• CLINICAL_TRIALS trial_result · 2016-02-26
  Clinical Trial Update: PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities [Phase 2]

  Phase 2 trial evaluating the safety and efficacy of Ingenol Mebutate Gel (PEP005) for superficial basal cell carcinoma on the trunk or extre…

• CLINICAL_TRIALS trial_result · 2015-02-27
  Clinical Trial Update: Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC [NA]

  This clinical trial update reports the termination of NCT00994240, a study evaluating cure rates for superficial basal cell carcinoma using …

• FDA label_change · 2011-07-15
  FDA Approved: ZYCLARA — Supplemental Application (Bausch Health US, LLC)

  FDA records a supplemental application for ZYCLARA (imiquimod) from Bausch Health US, LLC, filed to update the product labeling.

• FDA approval · 2011-04-15
  FDA Approved: IMIQUIMOD — Original Application (Sun Pharmaceutical Industries, Inc.)

  FDA approves Sun Pharmaceutical Industries' imiquimod generic under an Original Application (ANDA 200173) for the same indications as the br…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2010-09-07
  FDA Approved: IMIQUIMOD — Original Application (Padagis Israel Pharmaceuticals Ltd)

  The FDA approved Padagis Israel Pharmaceuticals Ltd's imiquimod generic (ANDA 078837) for actinic keratosis, superficial basal cell carcinom…